Key Takeaways From Agilon Health Analyst Ratings
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Agilon Health (NYSE:AGL) show a mix of sentiments, with a notable negative shift in the average 12-month price target to $7.12, down 32.19%. Analysts from firms like Citigroup, Barclays, and Truist Securities have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Agilon Health's financial health indicators such as market capitalization, revenue growth, net margin, ROE, and ROA are discussed, highlighting its position and performance in the healthcare sector.
April 22, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agilon Health has seen a negative shift in analyst sentiment, with the average 12-month price target reduced by 32.19% to $7.12. Financial indicators show strong revenue growth but challenges in profitability and efficiency.
The significant reduction in the average price target by analysts indicates a bearish outlook for Agilon Health in the short term. Despite strong revenue growth, the company's challenges in maintaining profitability and efficiency, as indicated by its net margin, ROE, and ROA, contribute to the negative sentiment. The detailed adjustments in ratings and price targets by analysts from reputable firms further underscore the cautious stance on Agilon Health's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100